Formulations of hydroxypyridonate actinide/lanthanide decorporation agents

Patent metadata

Field	Value
Publication number	US-12268678-B2
Application number	US-202217665135-A
Country	US
Kind code	B2
Filing date	Feb 4, 2022
Priority date	Sep 6, 2016
Publication date	Apr 8, 2025
Grant date	Apr 8, 2025

Abstract

Provided herein are pharmaceutical formulations comprising a 1,2-HOPO chelating agent and/or a 3,2-HOPO chelating agent.

First claim

What is claimed is:

1. A method for treating a subject for a heavy metal exposure, the method comprising:
administering to the subject having an excess amount of heavy metal a therapeutically effective amount of a pharmaceutical composition comprising:
a 1,2-HOPO chelating agent in an amount from about 100 mg to about 1500 mg; and
sodium oleate,

decorporating, clearing, and/or reducing the excess amount of heavy metal from the subject.

2. The method of claim 1 , wherein the subject has been exposed to, has been in contact with, or contaminated by one or more metals from the lanthanide series, the actinide series, or a mixture thereof.

3. The method of claim 2 , wherein the administering results in decorporating, clearing, and/or reducing the excess amount of actinide, lanthanide, or both from one or more systems and/or organs of the subject.

4. The method of claim 1 , wherein the heavy metal comprises one or more metals from the lanthanide series, the actinide series, or a mixture thereof.

5. The method of claim 1 , wherein the heavy metal comprises lead, tin, yttrium, scandium, and/or cadmium.

6. The method of claim 1 , wherein the 1,2-HOPO chelating agent is 3,4,3-LI-1,2-HOPO.

7. The method of claim 1 , wherein the sodium oleate is present at about 70 mg to about 130 mg.

8. The method of claim 1 , wherein the sodium oleate is present at 8 to 12% of a total weight of the pharmaceutical composition.

9. The method of claim 1 , wherein the sodium oleate is about 11% of a total weight of the pharmaceutical composition.

10. The method of claim 6 , wherein the 3,4,3-LI-1,2-HOPO is present in an amount from 300 mg to 1500 mg.

11. The method of claim 6 , wherein the 3,4,3-LI-1,2-HOPO is present in an amount from 400 mg to 1200 mg.

12. The method of claim 6 , wherein the 3,4,3-LI-1,2-HOPO is present in an amount from 100 mg to 300 mg.

13. The method of claim 6 , wherein the 3,4,3-LI-1,2-HOPO is present in an amount of 600 mg.

14. The method of claim 1 , wherein the pharmaceutical composition is a powder.

15. The method of claim 1 , wherein the pharmaceutical composition is a chewable tablet.

16. The method of claim 1 , wherein the pharmaceutical composition is an immediate release tablet.

17. The method of claim 1 , wherein the pharmaceutical composition is within one or more orally dispersible/dissolvable granules.

18. The method of claim 2 , wherein the administering is performed 24 hours after exposure to, contact with, and/or contamination by one or more metals.

19. The method of claim 1 , wherein the pharmaceutical composition comprises one or more additional ingredients.

20. The method of claim 19 , wherein the one or more additional ingredients comprise microcrystalline cellulose, carboxymethyl cellulose, croscarmellose sodium, guar gum, lactose monohydrate, hypromellose, magnesium stearate, povidone, crospovidone, mannitol, colloidal silicon dioxide, compressible sugar, pregelatinized starch, sodium starch glycolate, hydrogenated vegetable oil (type I), and polysorbate 80.

Assignees

• Univ California

Inventors

• Abergel Rebecca J
• Choi Taylor A
• Raymond Kenneth N
• Shuh David K

Classifications

• A61K9/2054

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title

• A61K9/2018

  Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates · CPC title

• A61K9/2009

  Inorganic compounds · CPC title

• A61K9/1652

  Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623) · CPC title

• A61K9/1623

  Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules · CPC title